Tonn Peter, Seule Lea, Degani Yoav, Herzinger Shani, Klein Amit, Schulze Nina
Neuropsychiatric Center of Hamburg, Hamburg, Germany.
VoiceSense Ltd, Herzelia, Israel.
JMIR Form Res. 2022 Aug 30;6(8):e37061. doi: 10.2196/37061.
Mood disorders and depression are pervasive and significant problems worldwide. These represent severe health and emotional impairments for individuals and a considerable economic and social burden. Therefore, fast and reliable diagnosis and appropriate treatment are of great importance. Verbal communication can clarify the speaker's mental state-regardless of the content, via speech melody, intonation, and so on. In both everyday life and clinical conditions, a listener with appropriate previous knowledge or a trained specialist can grasp helpful knowledge about the speaker's psychological state. Using automated speech analysis for the assessment and tracking of patients with mental health issues opens up the possibility of remote, automatic, and ongoing evaluation when used with patients' smartphones, as part of the current trends toward the increasing use of digital and mobile health tools.
The primary aim of this study is to evaluate the measurements of the presence or absence of depressive mood in participants by comparing the analysis of noncontentual speech parameters with the results of the Patient Health Questionnaire-9.
This proof-of-concept study included participants in different affective phases (with and without depression). The inclusion criteria included a neurological or psychiatric diagnosis made by a specialist and fluent use of the German language. The measuring instrument was the VoiceSense digital voice analysis tool, which enables the analysis of 200 specific speech parameters based on machine learning and the assessment of the findings using Patient Health Questionnaire-9.
A total of 292 psychiatric and voice assessments were performed with 163 participants (males: n=47, 28.8%) aged 15 to 82 years. Of the 163 participants, 87 (53.3%) were not depressed at the time of assessment, and 88 (53.9%) participants had clinically mild to moderate depressive phases. Of the 163 participants, 98 (32.5%) showed subsyndromal symptoms, and 19 (11.7%) participants were severely depressed. In the speech analysis, a clear differentiation between the individual depressive levels, as seen in the Patient Health Questionnaire-9, was also shown, especially the clear differentiation between nondepressed and depressed participants. The study showed a Pearson correlation of 0.41 between clinical assessment and noncontentual speech analysis (P<.001).
The use of speech analysis shows a high level of accuracy, not only in terms of the general recognition of a clinically relevant depressive state in the participants. Instead, there is a high degree of agreement regarding the extent of depressive impairment with the assessment of experienced clinical practitioners. From our point of view, the application of the noncontentual analysis system in everyday clinical practice makes sense, especially with the idea of a quick and unproblematic assessment of the state of mind, which can even be carried out without personal contact.
ClinicalTrials.gov NCT03700008; https://clinicaltrials.gov/ct2/show/NCT03700008.
情绪障碍和抑郁症是全球普遍存在的重大问题。这些问题给个人带来严重的健康和情感损害,也是相当大的经济和社会负担。因此,快速可靠的诊断和适当的治疗至关重要。言语交流可以通过语音旋律、语调等方式阐明说话者的心理状态,而不考虑内容。在日常生活和临床环境中,有相关知识的听众或训练有素的专家能够掌握有关说话者心理状态的有用信息。随着数字和移动健康工具的使用日益增加,将自动语音分析用于心理健康问题患者的评估和跟踪,为通过患者智能手机进行远程、自动和持续评估提供了可能。
本研究的主要目的是通过比较非内容性语音参数分析与患者健康问卷-9的结果,评估参与者是否存在抑郁情绪。
本概念验证研究纳入了处于不同情感阶段(有或无抑郁)的参与者。纳入标准包括由专科医生做出的神经或精神诊断以及流利使用德语。测量工具是VoiceSense数字语音分析工具,该工具能够基于机器学习分析200个特定语音参数,并使用患者健康问卷-9对结果进行评估。
对163名年龄在15至82岁的参与者(男性:n = 47,28.8%)进行了总共292次精神科和语音评估。在163名参与者中,87名(53.3%)在评估时未患抑郁症,88名(53.9%)参与者处于临床轻度至中度抑郁阶段。在163名参与者中,98名(32.5%)表现出亚综合征症状,19名(11.7%)参与者重度抑郁。在语音分析中,也显示出如患者健康问卷-9中所见的个体抑郁水平之间的明显差异,特别是未抑郁和抑郁参与者之间的明显差异。该研究显示临床评估与非内容性语音分析之间的Pearson相关性为0.41(P <.001)。
语音分析的应用不仅在总体上识别参与者临床相关抑郁状态方面显示出高度准确性。相反,在抑郁损害程度方面与经验丰富的临床医生的评估有高度一致性。从我们的角度来看,非内容性分析系统在日常临床实践中的应用是有意义的,特别是考虑到可以快速且顺利地评估心理状态,甚至无需面对面接触。
ClinicalTrials.gov NCT03700008;https://clinicaltrials.gov/ct2/show/NCT03700008